|
000
| 01871cam 2200409zi 4500 |
|---|
| 001 | 9.921323 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240103094627 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230327t20232023onc ob f000 0 eng d |
|---|
| 020 | |a9780660482057 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-327/2023E-PDF |
|---|
| 245 | 00|aGuidance on nitrosamine impurities in medications. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (iii, 25 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Date adopted: April 17, 2023. Effective date: April 17, 2023." |
|---|
| 500 | |aIssued also in French under title: Lignes directrices sur les impuretés de nitrosamine dans les médicaments. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"Evaluating and managing the risks of N-nitrosamine impurities in human pharmaceutical, biological and radiopharmaceutical products"--Cover. |
|---|
| 650 | 0|aNitrosoamines|xRisk assessment|zCanada. |
|---|
| 650 | 0|aDrugs|xRisk assessment|zCanada. |
|---|
| 650 | 0|aBiologicals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aRadiopharmaceuticals|xRisk assessment|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLignes directrices sur les impuretés de nitrosamine dans les médicaments.|w(CaOODSP)9.921324 |
|---|
| 794 | |tGuidance on nitrosamine impurities in medications.|bJuly 24, 2023|w(CaOODSP)9.924897 |
|---|
| 795 | |tGuidance on nitrosamine impurities in medications.|bSeptember 1, 2022|w(CaOODSP)9.914730 |
|---|
| 856 | 40|qPDF|s643 KB|uhttps://publications.gc.ca/collections/collection_2023/sc-hc/H164-327-2023-eng.pdf |
|---|